{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.5.', 'Appendix 5: Management of Potential IInfusion-Associated Adverse', 'Events During Study Drug Administration', 'Intravenous and infusion-associated reactions are a potential risk with the use of mAbs; these', 'reactions can be nonimmune or immune-mediated (eg, hypersensitivity reactions). Signs and', 'symptoms may include headache, fever, facial flushing, pruritus, myalgia, nausea, chest', 'tightness, dyspnea, vomiting, erythema, abdominal discomfort, diaphoresis, shivers,', 'hypertension, lightheadedness, hypotension, palpitations, and somnolence. Signs and symptoms', 'of hypersensitivity or allergic reactions may include hives, swollen face, eyelids, lips, or tongue,', 'or trouble with breathing.', 'All administration-, IV-, and infusion-associated reactions will be reported to the Investigator or', 'qualified designee (Section 8.3). The Investigator or qualified designee are responsible for', 'detecting, documenting, and recording events that meet the definition of AE or SAE and remain', 'responsible for following up events that are serious, considered related to the study drug, or', 'study procedures; or that caused the patient to discontinue the study drug (Section 7).', 'Definitions and procedures for recording, evaluating, follow-up, and reporting AEs and SAEs are', 'outlined in Section 10.3 (Appendix 3).', 'Patients who experience a reaction during the administration of study drug should be treated', 'according to institutional guidelines.', 'Patients who experience a severe reaction during administration of study drug resulting in', 'discontinuation of study drug should undergo all scheduled safety, PK, and PD evaluations', 'required by the protocol. The Sponsor must be notified within 24 hours of any infusion reaction', 'requiring interruption or discontinuation of study drug. All AEs that may indicate an', 'infusion-related response will be graded according to the CTCAE v5.0 or higher.', 'If anaphylaxis occurs according to the criteria listed below, then administration of SC', 'epinephrine (1/1000, 0.3 mL to 0.5 mL, or equivalent) should be considered. In the case of', 'bronchospasm, treatment with an inhaled beta agonist also should be considered. Patients', 'administered an antihistamine for the treatment or prevention of an infusion reaction should be', 'given appropriate warnings about drowsiness and impairment of driving ability before being', 'discharged from the center.', 'Page 80 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Clinical Criteria for Diagnosing Anaphylaxis:', 'Anaphylaxis is highly likely when any 1 of the following 3 criteria is fulfilled:', '(1) Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both', '(eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula), and at least 1 of the following:', 'a.', 'Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow', '(PEF), hypoxemia)', 'b. Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia [collapse], syncope,', 'incontinence)', '(2) Two or more of the following that occur rapidly after exposure to a likely allergen for that patient (minutes', 'to several hours):', 'a. Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen lips/tongue/uvula)', 'b. Respiratory compromise (eg, dyspnea, wheeze/bronchospasm, stridor, reduced PEF, hypoxemia)', 'c.', 'Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, incontinence)', 'd.', 'Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting)', '(3) Reduced BP after exposure to known allergen for that patient (minutes to several hours):', \"a. Systolic BP of less than 90 mmHg or greater than 30% decrease from that patient's baseline\", 'Abbreviations: BP = blood pressure; PEF = peak expiratory flow.', 'Source: Sampson, 2006', 'Page 81 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}